RxDoctor Payments Data

Russell Walker, MD

Allergy & Immunology · Murfreesboro, TNNPI 1871532184

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.3% of the total across 395 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 31 manufacturers reported payments, led by AstraZeneca at 24.8% of the total.

$8,275in general payments, 2019–2025

Across 395 payments — averaging $20.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • GSK$1K
  • CSL Behring$1K
  • Sanofi$631
  • Novartis$580
  • Regeneron Healthcare Solutions, Inc.$511
  • plus $2K from 25 others

What the payments were for

  • Food & beverage$8,21399%
  • Education$621%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,275 in reported general payments places this provider in the 60th percentile of 79 allergy & immunology providers in Tennessee.

See all allergy & immunology providers in Tennessee

Medicare billing

Part B allowed, 2024
$17,309
Medicare patients
95
Services billed
1,677

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XolairOmalizumab23$71,931
Trelegy ElliptaFluticasone/Umeclidin/Vilanter28$32,541
Breo ElliptaFluticasone/Vilanterol35$13,572
Advair HfaFluticasone Propion/Salmeterol14$4,096
Azelastine Hcl41$1,221
Albuterol Sulfate HfaAlbuterol Sulfate40$849
Montelukast Sodium43$606
Famotidine26$510
Fluticasone Propionate52$501
Levocetirizine Dihydrochloride19$175
Prednisone14$23

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta$1,354$46,11363 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 79 allergy & immunology providers in Tennessee.

Other allergy & immunology in Murfreesboro

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →